Arbutus Biopharma Corp ABUS

Healthcare Biotechnology

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for.

NDAQ:ABUS - Post by User

Arbutus Biopharma Corp

Bullboard Posts

Post by pool1212on Nov 13, 2012 8:44am

188 Views

Post# 20592237

Something to watch - invovlement of WOF

Definitely will be interesting to see what they will do moving forward.

Working opportunities Fund and Growth Works capital; although they had been selling as late as October 3 2012, their strategy will be of interest moving forward.

Please refer to recent press release Nov 2 from GrowthWorks as to stopping investor sales and redemptions until Dec 31, 2012.

https://www.growthworks.ca/news/fund-news.asp#working.

Still own in exccess of 10% of common shares of TKM and this window will enable them to capitalize upon a strategy to add considerable value to the funds, also creating needed resources to accommodate any liquidity.

worth a look into

regards

Bullboard Posts

Investors eye Australian gold mining projects amid promising developments